Hua Medicine Announces 2024 Annual Results - HuaTangNing completed its first full year for reimbursement under the National Reimbursement D ...

Ultimately, Chimerix’s board went with Jazz’s offer due to its cash payable nature and the recent downward trend in biopharma ...

Hims & Hers has risen since November 2024, outperforming the S&P 500. Click here to see why HIMS stock is a Buy.

Gold price has rallie over 1.00% at one point on Thursday after fresh tariff comments.

The EUR/USD pair rebounds from over a three-week low, around the 1.0735-1.0730 area touched during the Asian session on ...

Billionaire Ken Fisher, a prominent money manager, renowned author, and financial analyst, is the founder of Fisher Asset Management.

Much has been written about the demise of the traditional pharmaceutical sales model and the “Complex Buying Environment” that now pervades within our industry. The reasons have been well docu ...

Lexicon Pharmaceuticals Inc. (Nasdaq: LXRX) said March 28 it will exclusively license its drug candidate LX9581 to Danish ...

After much delay, Novartis has finally won a key FDA go-ahead for Pluvicto, opening up the radioligand therapy to a much ...

The passage of comprehensive healthcare reform will have a dramatic impact on pharmaceutical sales in the United States. The tightening of regulations and product formularies will result in less ...

Key takeaways The White House claims it will boost domestic manufacturing, but automakers warn of higher costs and lower sales due to ... tariffs on computer chips, pharmaceutical drugs, lumber ...